WORLD
Celltrion selected for state project to develop pen-type insulin biosimilar
WORLD

Celltrion selected for state project to develop pen-type insulin biosimilar

Published: June 3, 2020  |  1 min read, 218 words
WRITTEN BY
Your review will affect the following:
> >[Courtesy of Celltrion]SEOUL -- Celltrion, a bio firm in South Korea, will develop a pen-type insulin biosimilar. It has yet to decide which products will be used as an original medicine.Celltrion will be in charge of clinical trials and the development of an insulin biosimilar, while Poonglim Pharmatech, a domestic medical device manufacturer, will develop an automatic free-field pen-type injection. The two companies were selected for a state project supervised by the state-run Korea Evaluation Institute of Industrial Technology (KEIT) to develop customized diagnostic treatment... READ MORE
CRITIC
N/A
N/Ano rating
Critic Reviews: N/A
We calculate ratings after a minimum of three reviews.
USER
N/A
N/Ano rating
User Reviews: N/A
We calculate ratings after a minimum of three reviews.
TOP REVIEWS
There are no reviews yet.

CRITIC REVIEWS

There don't seem to be any reviews yet.

PUBLIC REVIEWS

There don't seem to be any reviews yet.